Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Safety milestone met in phase I/II bone grafting study of Tissue Repair Cells

Feb. 4, 2005

Nascobal Nasal Spray receives FDA approval

Feb. 4, 2005

Cathepsin K inhibitors emerge from Roche research

Feb. 3, 2005

Alizyme opens IND for ATL-962 study in U.S.

Feb. 3, 2005

Toxicity study for FM-VP4

Feb. 3, 2005

SkyePharma and First Horizon extend novel fenofibrate formulation agreement

Feb. 3, 2005

Flamel and Bristol-Myers Squibb resolve former Basulin license matters

Feb. 3, 2005

Six-month review for rhASB in treatment of MSP VI

Feb. 3, 2005

OSI scientists develop new glycogen phosphorylase inhibitors

Feb. 2, 2005

Icos and Solvay to copromote AndroGel

Feb. 2, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...